Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine Given in Japanese Subjects
Conditions
Interventions
Typhoid Vi polysaccharide
Locations
3
Japan
Nagoya, Aichi-ken, Japan
Osaka, Osaka, Japan
Shinjuku, Tokyo, Japan
Start Date
May 1, 2012
Primary Completion Date
September 1, 2012
Completion Date
December 1, 2012
Last Updated
May 12, 2014
NCT07286370
NCT06704048
NCT04263792
NCT06135350
NCT06103500
NCT02979951
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions